Status:
COMPLETED
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Lead Sponsor:
Sanjiv Sam Gambhir
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Adult Giant Cell Glioblastoma
Adult Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with...
Detailed Description
PRIMARY OBJECTIVE • Evaluate 18F-FPPRGD2 and 18F-FDG as PET/CT or PET/MRI radiotracers for imaging prediction and assessment of response to anti-angiogenesis therapy in participants with glioblastoma...
Eligibility Criteria
Inclusion
- Provides written informed consent
- Diagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis treatment or treatment with other drugs that may alter angiogenesis
- Able to remain still for duration of each imaging procedure (about one hour)
Exclusion
- Pregnant or nursing
- Contraindication to MRI
- History of renal insufficiency (only for MRI contrast administration)
Key Trial Info
Start Date :
March 4 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2019
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT01806675
Start Date
March 4 2013
End Date
April 1 2019
Last Update
October 3 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University, School of Medicine
Stanford, California, United States, 94305